Zoledronic acid cuts mortality after hip fracture

Article

In patients with low-trauma hip fracture, an annual infusion of zoledronic acid starting within 90 days of surgical repair of the fracture may decrease the risk of new fractures and improve survival.

In patients with low-trauma hip fracture, an annual infusion of zoledronic acid starting within 90 days of surgical repair of the fracture may decrease the risk of new fractures and improve survival, according to a study published online Sept. 17 in the New England Journal of Medicine.

Kenneth W. Lyles, MD, of the Duke University Medical Center in Durham, N.C., and colleagues randomly assigned 1,065 patients to receive either yearly intravenous zoledronic acid or placebo starting within 90 days after surgical repair of a hip fracture and followed them for a median of 1.9 years.

The researchers found that rates of any new clinical hip fracture were lower in the zoledronic acid group than in the placebo group (8.6 % versus 13.9%). They also found that the zoledronic acid group had a 28% lower risk of death from any cause, but that they also were more likely to experience side effects such as pyrexia, myalgia, and bone and musculoskeletal pain.

Lyles KW, Colón-Emeric CS,Magaziner JS, et al. Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture. N Engl J Med. 2007, Sep 26; [Epub ahead of print].

Recent Videos
Understanding and managing postpartum hemorrhage: Insights from Kameelah Phillips, MD | Image Credit: callawomenshealth.com
Rossella Nappi, MD, discusses benefits of fezolinetant against vasomotor symptoms | Image Credit: imsociety.org
How AI is revolutionizing breast cancer detection | Image Credit: simonmed.com
Understanding cardiovascular risk factors in women | Image Credit: cedars-sinai.org.
Christie Hilton, DO, discusses breast cancer management | Image Credit: findcare.ahn.org
Updated FLUBLOK label expands influenza vaccine options for pregnant women | Image Credit: mass-vaccination-resources.org
Sheryl Kingsberg, PhD: Psychedelic RE104 for postpartum depression
Mammograms may reveal hidden cardiovascular risks, study finds | Image Credit: providers.ucsd.edu
Erika Hamilton highlights emerging breast cancer trends and advances in treatment | Image Credit: sarahcannon.com
JoAnn Pinkerton discusses elinzanetant's crucial role in VMS therapy | Image Credit: uvahealth.com
© 2024 MJH Life Sciences

All rights reserved.